X4 Pharmaceuticals (XFOR) Operating Income (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Operating Income of -$23.7 million for Q4 2025, up 13.85% on a QoQ basis from -$27.5 million in Q3 2025, and up 33.64% year-over-year from -$17.7 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Operating Income (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Operating Income history runs 9 years deep, the most recent figure standing at -$23.7 million for Q4 2025.
- Quarterly Operating Income rose 33.64% year-over-year to -$23.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$86.9 million (down 138.68% YoY) and the FY2025 annual result came in at -$86.9 million, down 138.68% from the prior year.
- Operating Income was -$23.7 million for Q4 2025 at X4 Pharmaceuticals, up from -$27.5 million in the prior quarter.
- Across five years, Operating Income topped out at $71.1 million in Q2 2024 and bottomed at -$37.3 million in Q1 2024.
- A 5-year average of -$20.2 million and a median of -$25.4 million in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income surged 375.54% — and 2025, when it sank 136.89%.
- X4 Pharmaceuticals' Operating Income stood at -$29.1 million in 2021, then rose by 11.97% to -$25.6 million in 2022, then rose by 1.48% to -$25.2 million in 2023, then tumbled by 41.73% to -$35.7 million in 2024, then surged by 33.64% to -$23.7 million in 2025.
- Business Quant data shows XFOR's Operating Income at -$23.7 million in Q4 2025, -$27.5 million in Q3 2025, and -$26.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 268.64 Mn |
| 10 | X4 Pharmaceuticals | 167.69 Mn | -49.36 Mn | 2.20 Mn | -23.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.70 Mn |
| Sep 30, 2025 | -27.51 Mn |
| Jun 30, 2025 | -26.23 Mn |
| Mar 31, 2025 | -9.44 Mn |
| Dec 31, 2024 | -35.72 Mn |
| Sep 30, 2024 | -34.50 Mn |
| Jun 30, 2024 | 71.10 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Dec 31, 2023 | -25.20 Mn |
| Sep 30, 2023 | -27.21 Mn |
| Jun 30, 2023 | -25.81 Mn |
| Mar 31, 2023 | -29.30 Mn |
| Dec 31, 2022 | -25.58 Mn |
| Sep 30, 2022 | -20.15 Mn |
| Jun 30, 2022 | -20.57 Mn |
| Mar 31, 2022 | -21.27 Mn |
| Dec 31, 2021 | -29.06 Mn |
| Sep 30, 2021 | -19.12 Mn |
| Jun 30, 2021 | -19.00 Mn |
| Mar 31, 2021 | -17.94 Mn |